India, June 14 -- Serum Institute of India (SII) on Friday signed a memorandum of understanding (MoU) with not-for-profit medical research organisation Drugs for Neglected Diseases initiative (DNDi) to accelerate clinical development of a monoclonal antibody treatment for dengue that will be affordable and accessible in low-and middle-income countries (LMICs).

SII and DNDi will develop a work plan to implement research and development, Phase 3 clinical trials, and access activities, along with a joint strategy to raise the necessary funds and resources.

SII stated that it has already conducted pre-clinical studies and Phase 1 and 2 clinical trials that show the candidate is safe and effective. It is currently leading the Phase 3 clinica...